| Name | Title | Contact Details |
|---|
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.
QoL Meds is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We believe that our Hypermatrix technology is a novel and robust controlled-release drug delivery platform. This unique technology allows us to provide life-cycle management or new chemical entity delivery system solutions for virtually any small molecule. The flexibility of this technology allows us to quickly develop complex drug delivery solutions.
Neurana Pharmaceuticals is a privately held clinical stage San Diego based specialty pharmaceutical company developing a novel treatment for acute muscle spasms. The Company was founded in 2013 by veteran biotech entrepreneurs David F. Hale and Jeffrey Raser to focus on central nervous system (CNS) diseases and disorders.
Purdue Pharma is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.